Iqvia holdings inc.IQV.US Overview
IQV Overall Performance
IQV AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
IQV Current Performance
-0.29%
Iqvia holdings inc.
-0.58%
Avg of Sector
0.83%
S&P500
IQV Key Information
IQV Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
IQV Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
IQV Profile
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Price of IQV
IQV FAQ
When is IQV's latest earnings report released?
The most recent financial report for Iqvia holdings inc. (IQV) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IQV's short-term business performance and financial health. For the latest updates on IQV's earnings releases, visit this page regularly.
Where does IQV fall in the P/E River chart?
According to historical valuation range analysis, Iqvia holdings inc. (IQV)'s current price-to-earnings (P/E) ratio is 25.75, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of IQV?
According to the latest financial report, Iqvia holdings inc. (IQV) reported an Operating Profit of 506M with an Operating Margin of 12.6% this period, representing a decline of 2.69% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is IQV's revenue growth?
In the latest financial report, Iqvia holdings inc. (IQV) announced revenue of 4.02B, with a Year-Over-Year growth rate of 5.32%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does IQV have?
As of the end of the reporting period, Iqvia holdings inc. (IQV) had total debt of 15.7B, with a debt ratio of 0.55. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does IQV have?
At the end of the period, Iqvia holdings inc. (IQV) held Total Cash and Cash Equivalents of 2.04B, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does IQV go with three margins increasing?
In the latest report, Iqvia holdings inc. (IQV) achieved the “three margins increasing” benchmark, with a gross margin of 32.9%%, operating margin of 12.6%%, and net margin of 6.6%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IQV's profit trajectory and future growth potential.
Is IQV's EPS continuing to grow?
According to the past four quarterly reports, Iqvia holdings inc. (IQV)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.55. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of IQV?
Iqvia holdings inc. (IQV)'s Free Cash Flow (FCF) for the period is 292M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 37.87% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of IQV?
The latest valuation data shows Iqvia holdings inc. (IQV) has a Price-To-Earnings (PE) ratio of 25.75 and a Price/Earnings-To-Growth (PEG) ratio of 2.78. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.